Company Immuno News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations

/PRNewswire/ Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with.

Mark gergenGeorgem churchChristine brownMadhu natarajanCompany immunoCompany gene therapy scientific advisory boardPoseida therapeutics incOncology annual congressEuropean society for medical oncology immunoVirtual rd dayPoseida therapeuticsChief executive officerGene therapy scientific advisory boardRare diseases drug discovery unitImmuno oncology scientific advisoryEuropean society

Investegate |Oncimmune Hldgs PLC Announcements | Oncimmune Hldgs PLC: Proposed Placing and Subscription

Investegate announcements from Oncimmune Hldgs PLC, Proposed Placing and Subscription

United statesNew zealandUnited kingdomSouth africaCity ofRepublic of south africaNorfolk waveneyAubrey powellErland sternbyOncimmune immunoDavid wilsonAdamm hillJohn gooldMatthew hallNigel barnesHarry gooden

Imfinzi plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up

Imfinzi plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up
astrazeneca.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from astrazeneca.com Daily Mail and Mail on Sunday newspapers.

France generalSoult ukpyolsiSouth koreaUnited statesUnited kingdomAstrazeneca imfinziDaiichi sankyoSusan galbraithCompany immunoSeoul national university college of medicineCompany on twitter astrazenecaMerck co incJapan clinical oncology group studyInvestor relations teamDivision of medical oncologyEuropean society for medical oncology

AstraZeneca s (AZN) IMFINZI Plus Chemotherapy Improved Overall Survival Benefit in TOPAZ-1 Phase III Trial

AstraZeneca s (AZN) IMFINZI Plus Chemotherapy Improved Overall Survival Benefit in TOPAZ-1 Phase III Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France generalSoult ukpyolsiSouth koreaUnited statesUnited kingdomJessica mcduellSouth east asiaDaiichi sankyoBrendan mcevoyGastroenterol hepatolSusan galbraithCompany immunoNational comprehensive cancer network incSeoul national university college of medicineMerck co incCompany on twitter astrazeneca

AstraZeneca: IMFINZI (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up

HIMALAYA Phase III trial exploratory results support the benefit of tremelimumab added to IMFINZI in unresectable liver cancer regardless of etiology Updated results from the TOPAZ-1 Phase III trial

France generalSoult ukpyolsiSouth koreaUnited statesUnited kingdomJessica mcduellSouth east asiaDaiichi sankyoBrendan mcevoyGastroenterol hepatolSusan galbraithCompany immunoNational comprehensive cancer network incSeoul national university college of medicineMerck co incCompany on twitter astrazeneca